Leucocyte antibodies in blood donors and a look back on recipients of their blood components

Institute of Haematology and Blood Transfusion, Warsaw, Poland.
Vox Sanguinis (Impact Factor: 2.8). 05/2007; 92(3):247-9. DOI: 10.1111/j.1423-0410.2007.00890.x
Source: PubMed


The role of leucocyte antibodies in donors is poorly understood in pathogenesis of transfusion-related acute lung injury (TRALI). We examined antibodies in donors and traced recipients transfused with their blood components.
Antibodies were examined in 1043 donors by five methods, look back performed in 26 recipients.
Anti-human leucocyte antigen detected by enzyme-linked immunosorbent assay in 9.8% women but none in men. Specificities identified using FlowPRA, antibodies detected after several months. TRALI reported in one recipient from immunized donor. In 11 of 26 recipients without TRALI, cognate antigens were identified.
Detection of antibodies in donors cannot predict TRALI, even in recipients with cognate antigen(s).

Download full-text


Available from: Jacek Nowak,
  • [Show abstract] [Hide abstract]
    ABSTRACT: One of the high-power limitations encountered in modern sonar systems is caused by the mutual interaction effect among the densely packed elements of projector arrays. This causes severe and complex effects at higher drive levels. This effect can be minimized by restructuring the array format with suitable selection of appropriate interelement spacing. The design considerations of uniform linear projector array formats that minimize the mutual interaction effect are presented. The radiation pattern and array gain of the proposed array are found to be improved, as far as certain signal and noise models are concerned
    Acoustics, Speech, and Signal Processing, 1988. ICASSP-88., 1988 International Conference on; 05/1988
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Antibodies directed against human leukocyte antigens (HLA) are involved in graft failure, as well as in platelet refractoriness. Therefore, HLA antibody screening prior to renal transplantation is mandatory. Since the introduction of the complement-dependent cytotoxic test in the 1960s, this assay has become the gold standard of HLA serology. It is based on complement fixation and cell lysis provoked by cytotoxic HLA class I antibodies. Non-cytotoxic antibodies will not be detected. In the meantime, additional methods based on different analytical approaches have been developed. Today, particularly enzyme-linked immunosorbent assays (ELISA) are commercially available for HLA antibody screening and specificity determination. HLA class I- and/or class II-specific antibodies can be detected. Flow cytometry had been introduced early as a method for HLA antibody detection, but was not widely applied as a routine method for a long time. Similarly, this applies to the immune phagocytosis inhibition test, which is successfully performed in only a handful of laboratories. The different assays are based on distinct mechanisms and therefore only partly detect the same antibodies. All, except for the complement-dependent cytotoxic test, detect both cytotoxic and non-cytotoxic antibodies. Selective detection of antibodies of the IgG class or restricted detection of HLA class I antibodies are further limiting parameters of some of the methods. In this review, a survey of the methods for the detection of HLA antibodies is provided, and the advantages and disadvantages of each method are discussed. Zusammenfassung: Antikörper gegen Humane Leukozyten Antigene (HLA) sind sowohl an der Transplantatabstoßung wie auch an Refraktärzuständen nach Thrombozytentransfusionen beteiligt. Aus diesem Grund ist ein HLA-Antikörper-Screening vor einer Nierentransplantation unerlässlich. Seit der Einführung des Komplement-abhängigen zytotoxischen Testes in den Sechziger Jahren hat sich dieser Test zum Goldstandard der HLA-Serologie entwickelt. Er basiert auf der HLA-Antikörper-induzierten Komplement-Fixierung mit anschließender Zytolyse. Nicht-zytotoxische Antikörper werden auf diese Weise nicht erfasst. In der Zwischenzeit wurden zusätzliche Tests entwickelt, die auf unterschiedlichen methodischen Ansätzen beruhen. Insbesondere Enzymimmunoassays (ELISA) für das HLA-Antikörper-Screening und zur Spezifitätsbestimmung sind mittlerweile kommerziell erhältlich. Sowohl HLA-Klasse I-, wie auch HLA-Klasse II-spezifische Antikörper können mit solchen Testen nachgewiesen werden. Die Durchflusszytometrie wurde bereits früh als Methode zum Nachweis von HLA-Antikörpern beschrieben, allerdings blieb ihr der Einzug als Routinemethode lange versperrt. Dies gilt auch für Immunphagozytose-Inhibitions-Teste, die erfolgreich in wenigen Laboren angewendet werden. Da die verschiedenen Teste auf unterschiedlichen Mechanismen beruhen, weisen sie auch nur zum Teil dieselben Antikörper nach. Mit Ausnahme des Komplement-abhängigen zytotoxischen Testes weisen alle anderen Teste sowohl zytotoxische, wie auch nicht-zytotoxische Antikörper nach. Weitere Einschränkungen einzelner Teste beziehen sich auf den selektiven Nachweis von Antikörpern der IgG-Klasse oder den ausschließlichen Nachweis von HLA-Klasse I-spezifischen Antikörpern. Im Folgenden soll eine Übersicht über die verschiedenen Methoden zum serologischen Nachweis von HLA-Antikörpern gegeben werden und die Vor- und Nachteile der einzelnen Testverfahren diskutiert werden.
    Laboratoriums Medizin 11/2003; 27(9‐10):351 - 358. DOI:10.1046/j.1439-0477.2003.03067.x · 0.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transfusion-related acute lung injury (TRALI) is underdiagnosed and underreported. This is why we present cases suspected for TRALI, in which leucocyte antibodies were examined. We analysed 44 patients with respiratory insufficiency, related to transfusion, who met criteria of acute lung injury (ALI). Lymphocyte and granulocyte antibodies were examined in donors and patients by six methods. Based on recent trends, we divided patients into two groups: TRALI (without risk factors for ALI) and possible TRALI (with probable risk factors). The incidence of antibodies was 68.2%, the majority were human leucocyte antigen (HLA) class I and/or II, the minority were non-specific granulocyte antibodies; half of all detected antibodies, however, reacted with granulocytes. Antibodies were found in 17 donors (more often in TRALI than in possible TRALI) and in 19 patients (in four - suspected to be of the donor origin, which would diminish the number of antibodies to 15). In seven available cases, we observed cognate antigen and/or positive cross-match. In the majority of patients, TRALI occurred after transfusion of red cells, in 56.2%- stored above 14 days; all the units were non-leucoreduced. Lookback in two donors showed that transfusions in 20 patients did not result in reported TRALI, even in the patient with cognate antigen. Our clinical observations suggest that to distinguish between TRALI and possible TRALI is difficult and the results are equivocal - it is worth considering whether it can be omitted. We have confirmed that antibodies are involved in TRALI, although their role is very complex. The role of stored red blood cells in the development of TRALI requires further observations in comparison with a control group of patients without TRALI.
    Vox Sanguinis 08/2007; 93(1):70-7. DOI:10.1111/j.1423-0410.2007.00920.x · 2.80 Impact Factor
Show more